G-protein-coupled receptors and asthma endophenotypes: The cysteinyl leukotriene system in perspective

Molecular Diagnosis and Therapy

Volumn 10, Issue 6, 2006, Pages 353-366

  Thompson, Miles D ^a,f   Takasaki, Jun ^b   Capra, Valérie ^c   Rovati, G Enrico ^c   Siminovitch, Kathy A ^d   Burnham, W McIntyre ^a   Hudson, Thomas J ^e   Bossé, Yohan ^e   Cole, David E C ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b ASTELLAS PHARMA INC   (Japan)

^c UNIVERSITY OF MILAN   (Italy)

^d MOUNT SINAI HOSPITAL   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA 2 ADRENERGIC RECEPTOR; CHEMOKINE; CHEMOKINE RECEPTOR CCR5; CYSTEINYL LEUKOTRIENE 1 RECEPTOR; CYSTEINYL LEUKOTRIENE 2 RECEPTOR; ENDOTHELIN 1; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR ASSOCIATED WITH ASTHMA; LEUKOTRIENE RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONTELUKAST; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDOLEUKOTRIENE; PRANLUKAST; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN RECEPTOR; RANTES; SALBUTAMOL; THROMBOXANE; THROMBOXANE A2 RECEPTOR; ZAFIRLUKAST;

ASPIRIN INTOLERANT ASTHMA; ASTHMA; ATOPY; BRONCHUS HYPERREACTIVITY; DISEASE ACTIVITY; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESPONSE; GENE INTERACTION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 33845513409     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256212     Document Type: Review

References (163)

1. Lynch KR, O'Neill GP, Liu QY, et al. Characterization of the human cysteinyl leukotriene CysLT(1) receptor. Nature 1999; 399 (6738): 789-93
2. Heise CE, O'Dowd BF, Figueroa DJ, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 2000; 275: 30531-6
3. Bisgaard H. Role of leukotrienes in asthma pathophysiology. Pediatr Pulmonol 2000; 30: 166-76
4. Bisgaard H. Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma. Allergy 2001; 56: 7-11
5. Thompson MD, Gravesandeg KSV, Galczenski H, et al. A cysteinyl leukotriene 2 receptor variant is associated with atopy in the population of Tristan da Cunha. Pharmacogenetics 2003; 13: 641-9
6. In KH, Asano K, Beier D, et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997; 99: 1130-7
7. Israel E, Drazen JM, Liggett SB, et al. Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma. Int Arch Allergy Immunol 2001; 124: 183-6
8. Israel E, Drazen JM, Liggett SB, et al. The effect of polymorphisms of the beta(2)- adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162: 75-80
9. Oguma T, Palmer LJ, Birben E, et al. Role of prostanoid DP receptor variants in susceptibility to asthma. N Engl J Med 2004; 351: 1752-63
10. Cookson W, Moffatt M. Making sense of asthma genes. N Engl J Med 2004; 351: 1794-6
11. Kormann MSD, Carr D, Klopp N, et al. G-protein-coupled receptor polymorphisms are associated with asthma in a large German population. Am J Respir Crit Care Med 2005; 171: 1358-62
12. Melen E, Bruce S, Doekes G, et al. Haplotypes of G protein-coupled receptor 154 are associated with childhood allergy and asthma. Am J Respir Crit Care Med 2005; 171: 1089-95
13. Liggett SB. Polymorphisms of the beta(2)-adrenergic receptor and asthma. Am J Respir Crit Care Med 1997; 156 (4 Pt 2): S156-62
14. Thompson MD, Burnham WM, Cole DEC. The G protein-coupled receptors: pharmacogenetics and disease. Crit Rev Clin Lab Sci 2005; 42: 311-92
15. Sibbald B. Extrinsic and intrinsic asthma: influence of classification on family history of asthma and allergic disease. Clin Allergy 1980; 10: 313-8
16. John B, Lewis KR. Chromosome variability and geographic distribution in insects: chromosome rather than gene variation provide the key to differences among populations. Science 1966; 152: 711-21
17. Gottesman II, Shields J. A polygenic theory of schizophrenia. Proc Natl Acad Sci U S A 1967; 58: 199-205
18. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003; 160: 636-45
19. Marsh DG, Neely JD, Breazeale DR, et al. Linkage analysis of Il4 and other chromosome 5Q31.1 markers and total serum immunoglobulin E concentrations. Science 1994; 264: 1152-6
20. Panhuysen CIM, Bleecker ER, Koeter GH, et al. Dutch approach to the study of the genetics of asthma. Clin Exp Allergy 1995; 25: 35-8
21. Dickson PW, Wong ZYH, Harrap SB, et al. Mutational analysis of the high affinity immunoglobulin E receptor beta subunit gene in asthma. Thorax 1999; 54: 409-12
22. Hemmingsen A, Fryer AA, Strange RC, et al. Polymorphism at the glutathione Stransferase: GSTP1 locus is associated with isocyanate-induced asthma: use of an ARMS-PCR assay for the simultaneous determination of (I105-V105) and A(114)-V-114 alleles. Chem Biol Interact 2001; 133: 120-2
23. Fryer AA, Spiteri MA, Bianco A, et al. The 403 G>A promoter polymorphism in the RANTES gene is associated with atopy and asthma. Genes Immun 2000; 1: 509-14
24. Hill MR, James AL, Faux JA, et al. Fc epsilon RI-beta polymorphism and risk of atopy in a general population sample. BMJ 1995 Sep 23; 311(7008): 776-9. Erratum in: BMJ 1995 Nov 4; 311 (7014): 1196
25. Leff AR. Regulation of leukotrienes in the management of asthma: biology and clinical therapy. Annu Rev Med 2001; 52: 1-14
26. Jinnai N, Sakagami T, Sekigawa T, et al. Polymorphisms in the prostaglandin E-2 receptor subtype 2 gene confer susceptibility to aspirin-intolerant asthma: a candidate gene approach. Hum Mol Genet 2004; 13: 3203-17
27. Nicolae D, Cox NJ, Lester LA, et al. Fine mapping and positional candidate studies identify HLA-G as an asthma susceptibility gene on chromosome 6p21. Am J Hum Genet 2005; 76: 349-57
28. Weiss LA, Lester LA, Gern JE, et al. Variation in ITGB3 is associated with asthma and sensitization to mold allergen in four populations. Am J Respir Crit Care Med 2005; 172: 67-73
29. Cookson WOC, Moffatt MF. Genetics of asthma and allergic disease. Hum Mol Genet 2000; 9: 2359-64
30. Van Eerdewegh P, Little RD, Dupuis J, et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 2002; 418: 426-30
31. Davies DE, Wicks J, Powell RM, et al. Airway remodeling in asthma: new insights. J Allergy Clin Immunol 2003; 111: 215-25
32. Bruyninckx WJ, Comerford KM, Lawrence DW, et al. Phosphoinositide 3-kinase modulation of beta(3)-integrin represents an endogenous "braking" mechanism during neutrophil transmatrix migration. Blood 2001; 97: 3251-8
33. Bourgain C, Hoffjan S, Nicolae R, et al. Novel case-control test in a founder population identifies P-selectin as an atopy-susceptibility locus. Am J Hum Genet 2003; 73: 612-26
34. Mao XQ, Gao PS, Roberts MH, et al. Variants of endothelin-1 and its receptors in atopic asthma. Biochem Biophys Res Commun 1999; 262: 259-62
35. Holla LI, Vasku A, Izakovic V, et al. Variants of endothelin-1 gene in atopic diseases. J Investig Allergol Clin Immunol 2001; 11: 193-8
36. Summerhill E, Leavitt SA, Gidley H, et al. Beta(2)-adrenergic receptor Arg16/Arg16 genotype is associated with reduced lung function, but not with asthma, in the Hutterites. Am J Respir Crit Care Med 2000; 162: 599-602
37. Sadee W, Hoeg E, Lucas J, et al. Genetic variations in human G protein-coupled receptors: implications for drug therapy. AAPS Pharmsci 2001; 3 (3): e22
38. Small KM, Mcgraw DW, Liggett SB. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 2003; 43: 381-411
39. Turki J, Pak J, Green SA, et al. Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma: evidence that Gly16 correlates with the nocturnal phenotype. J Clin Invest 1995; 95 (4): 1635-41
40. Contopoulos-Ioannidis DG, Manoli EN, Ioannidis JP. Meta-analysis of the associa-tion of beta2-adrenergic receptor polymorphisms with asthma phenotypes. J Allergy Clin Immunol 2005; 115 (5): 963-72
41. Martinez FD, Graves PE, Baldini M, et al. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997; 100: 3184-8
42. Dewar JC, Wilkinson J, Wheatley A, et al. The glutamine 27 beta(2)-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families. J Allergy Clin Immunol 1997; 100: 261-5
43. Large V, Hellstrom L, Reynisdottir S, et al. Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. J Clin Invest 1997; 100: 3005-13
44. Drysdale CM, Mcgraw DW, Stack CB, et al. Complex promoter and coding region beta(2)-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 2000; 97: 10483-8
45. Wagoner LE, Craft LL, Singh B, et al. Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure. Circ Res 2000; 86 (8): 834-40
46. Reihsaus E, Innis M, Macintyre N, et al. Mutations in the gene encoding for the beta-2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993; 8: 334-9
47. Dishy V, Landau R, Sofowora G, et al. Beta-2-adrenoceptor thr164ile polymorphism is associated with markedly decreased vasodilator and increased vasoconstrictor sensitivity in vivo. Pharmacogenetics 2004; 14: 517-22
48. Lachance M, Ethier N, Wolbring G, et al. Stable association of G proteins with beta 2AR is independent of the state of receptor activation. Cell Signal 1999; 11 (7): 523-33
49. Nagata K, Hirai H, Tanaka K, et al. CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett 1999; 459: 195-9
50. Nagata K, Tanaka K, Ogawa K, et al. Selective expression of a novel surface molecule by human Th2 cells in vivo. J Immunol 1999; 162: 1278-86
51. Cosmi L, Annunziato F, Iwasaki M, et al. CRTH2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and disease. Eur J Immunol 2000; 30: 2972-9
52. Dogne JM, de Leval X, Benoit P, et al. Therapeutic potential of thromboxane inhibitors in asthma. Expert Opin Investig Drugs 2002; 11: 275-81
53. Citro S, Ravasi S, Rovati GE, et al. Thromboxane prostanoid receptor signals through G(i) protein to rapidly activate extracellular signal-regulated kinase in human airways. Am J Respir Cell Mol Biol 2005; 32: 326-33
54. Kim SH, Choi JH, Park HS, et al. Association of thromboxane A2 receptor gene polymorphism with the phenotype of acetyl salicylic acid-intolerant asthma. Clin Exp Allergy 2005; 35: 585-90
55. Leung TF, Tang NLS, Lam CWK, et al. Thromboxane A2 receptor polymorphism is associated gene with the serum concentration of cat-specific immunoglobulin E as well as the development and severity of asthma in Chinese children. Expert Opin Investig Drugs 2002; 13: 10-7
56. Shin HD, Park BL, Jung JH, et al. Association of thromboxane A2 receptor (TBXA2R) with atopy and asthma. J Allergy Clin Immunol 2003; 112: 454-7
57. Unoki M, Furuta S, Onouchi Y, et al. Association studies of 33 single nucleotide polymorphisms (SNPs) in 29 candidate genes for bronchial asthma: positive association a T924C polymorphism in the thromboxane A2 receptor gene. Hum Genet 2000; 106: 440-6
58. Thompson MD, Zamel N, Slutsky AS, et al. Genetic variants in both cysteinyl leukotriene 1 and 2 receptors are independently associated with atopy and asthma in a Tristan da Cunha population [abstract]. Eur J Hum Genet 2005; 13: P1066
59. Thompson MD, Storm K, Galczenski H, et al. A cysteinyl leukotriene 2 (CysLT(2)) receptor variant associated with atopy in the population of Tristan da Cunha. Am J Hum Genet 2002; 71: 207
60. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722-5
61. Hall IP, Wheatley A, Christie G, et al. Association of CCR5 del 32 with reduced risk of asthma. Lancet 1999; 354: 1264-5
62. Batra J, Sharma M, Chatterjee R, et al. CCR5 delta 32 deletion and atopic asthma in India [letter]. Thorax 2005; 60: 85
63. Srivastava P, Helms PJ, Stewart D, et al. Association of CCR5 delta 32 with reduced risk of childhood but not adult asthma. Thorax 2003; 58: 222-6
64. Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998; 187: 129-34
65. Agrawal DK, Bharadwaj A. Allergic airway inflammation. Curr Allergy Asthma Rep 2005; 5: 142-8
66. Kere J, Laitinen T. Positionally cloned susceptibility genes in allergy and asthma. Curr Opin Immunol 2004; 16: 689-94
67. Laitinen T, Polvi A, Rydman P, et al. Characterization of a common susceptibility locus for asthma-related traits. Science 2004; 304: 300-4
68. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. Eur Respir J 2000; 16: 432-6
69. Pierzchalska M, Szabo Z, Sanak M, et al. Deficient prostaglandin E-2 production by bronchial fibroblasts of asthmatic patients, with special reference to aspirin-induced asthma. J Allergy Clin Immunol 2003; 111: 1041-8
70. Cowburn AS, Sladek K, Soja J, et al. Overexpression of leukotriene C-4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998; 101: 834-46
71. Lam BK, Austen KF. Leukotriene C-4 synthase: a pivotal enzyme in the biosynthesis of the cysteinyl leukotrienes. Am J Respir Crit Care Med 2000; 161: S16-19
72. Sampson AP, Cowburn AS, Sladek K, et al. Profound overexpression of leukotriene C-4 synthase in bronchial biopsies from aspirin-intolerant asthmatic patients. Int Arch Allergy Immunol 1997; 113: 355-7
73. Sanak M, Pierzchalska M, Bazan-Socha S, et al. Enhanced expression of the leukotriene C-4 synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol 2000; 23: 290-6
74. Antczak A, Montuschi P, Kharitonov S, et al. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med 2002; 166: 301-6
75. Sanak M, Simon HU, Szczeklik A. Leukotriene C-4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997; 350: 1599-600
76. Van Sambeek R, Stevenson DD, Baldasaro M, et al. 5′ Flanking region polymorphism of the gene encoding leukotriene C-4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. J Allergy Clin Immunol 2000; 106: 72-6
77. Kawagishi Y, Mita H, Taniguchi M, et al. Leukotriene C-4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. J Allergy Clin Immunol 2002; 109: 936-42
78. Park JS, Chang HS, Park CS, et al. Association analysis of cysteinyl-leukotriene receptor 2 (CYSLTR2) polymorphisms with aspirin intolerance in asthmatics. Pharmacogenet Genomics 2005; 15: 483-92
79. Choi JH, Park HS, Oh HB, et al. Leukotriene-related gene polymorphisms in ASA-intolerant asthma: an association with a haplotype of 5-lipoxygenase. Hum Genet 2004; 114: 337-44
80. Taylor GW, Black P, Turner N, et al. Urinary leukotriene-E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989; I: 584-8
81. Kikawa Y, Miyanomae T, Inoue Y, et al. Urinary leukotriene E4 after exercise challenge in children with asthma. J Allergy Clin Immunol 1992; 89: 1111-9
82. Asano K, Lilly CM, Odonnell WJ, et al. Diurnal-variation of urinary leukotriene E(4) and histamine excretion rates in normal subjects and patients with mild-to-moderate asthma. J Allergy Clin Immunol 1995; 96: 643-51
83. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983; 220: 568-75
84. Duffy DL, Martin NG, Battistutta D, et al. Genetics of asthma and hay-fever in Australian twins. Am Rev Respir Dis 1990; 142: 1351-8
85. Shirakawa T, Mao XQ, Sasaki S, et al. Association between Fc epsilon RI beta and atopic disorder in a Japanese population. Lancet 1996; 347: 394-5
86. Ober C, Tsalenko A, Parry R, et al. A second-generation genomewide screen for asthma-susceptibility alleles in a founder population. Am J Hum Genet 2000; 67: 1154-62
87. Thomas NS, Wilkinson J, Lonjou C, et al. Linkage analysis of markers on chromosome 11q13 with asthma and atopy in a United Kingdom population. Am J Respir Crit Care Med 2000; 162: 1268-72
88. Greenwood CM, Bureau A, Loredo-Osti JC, et al. Pedigree selection and tests of linkage in a Hutterite asthma pedigree. Am Rev Respir Dis 2001; 21: S244-51
89. Gao PS, Mao XQ, Baldini M, et al. Serum total IgE levels and CD14 on chromosome 5q31. Clin Genet 1999; 56: 164-5
90. Adra CN, Mao XQ, Kawada H, et al. Chromosome 11q13 and atopic asthma. Clin Genet 1999; 55: 431-7
91. Donato JL, Cai HB, Adra CN. The subcellular distribution of HTm4, a hematopoietic specific protein and a canditade gene for atopy: identification of the CDK-associated phosphatase KAP as an interacting protein [abstract]. Am J Hum Genet 1999; 65: A269
92. Gao PS, Mao XQ, Jouanguy E, et al. Nonpathogenic common variants of IFNGR1 and IFNGR2 in association with total serum IgE levels. Biochem Biophys Res Commun 1999; 263: 425-9
93. Zhang YM, Leaves NI, Anderson GG, et al. Positional cloning of a quantitative trait locus on chromosome 13q14 that influences immunoglobulin E levels and asthma. Nat Genet 2003; 34: 181-6
94. Daniels SE, Bhattacharrya S, James A, et al. A genome-wide search for quantitative trait loci underlying asthma. Nature 1996; 383: 247-50
95. Liggett SB. The pharmacogenetics of beta(2)-adrenergic receptors: relevance to asthma. J Allergy Clin Immunol 2000; 105 (2 Pt 2): S487-92
96. Spik I, Brenuchon C, Angeli V, et al. Activation of the prostaglandin D-2 receptor DP2/CRTH2 increases allergic inflammation in mouse. J Immunol 2005; 174: 3703-8
97. Hirai H, Tanaka K, Yoshie O, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001; 193: 255-61
98. Huang JL, Gao PS, Mathias RA, et al. Sequence variants of the gene encoding chemoattractant receptor expressed on Th2 cells (CRTH2) are associated with asthma and differentially influence mRNA stability. Hum Mol Genet 2004; 13: 2691-7
99. Aizawa H, Shigyo M, Nogami H, et al. BAY u3405, a thromboxane A2 antagonist, reduces bronchial hyperresponsiveness in asthmatics. Chest 1996; 109: 338-42
100. Fujimura M, Nakatsumi Y, Nishi K, et al. Involvement of thromboxane A2 in bronchial hyperresponsiveness of asthma: Kanazawa asthma research group. Pulm Pharmacol 1995; 8: 251-7
101. Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Investig 2001; 108: 25-30
102. Capra V, Habib A, Accomazzo MR, et al. Thromboxane prostanoid receptor in human airway smooth muscle cells: a relevant role in proliferation. Eur J Pharmacol 2003; 474: 149-59
103. Devillier P, Bessard G. Thromboxane A(2) and related prostaglandins in airways. Fundam Clin Pharmacol 1997; 11: 2-18
104. Nishimura H, Tokuyama K, Inoue Y, et al. Acute effects of prostaglandin D-2 to induce airflow obstruction and airway microvascular leakage in guinea pigs: role of thromboxane A(2) receptors. Prostaglandins Other Lipid Mediat 2001; 66: 1-15
105. Meyers JH, Chakravarti S, Schlesinger D, et al. TIM-4 is the ligand for TIM-1, and the TIM-1-TIM-4 interaction regulates T cell proliferation. Nat Immunol 2005; 6: 455-64
106. Allen M, Heinzmann A, Noguchi E, et al. Positional cloning of a novel gene influencing asthma from Chromosome 2q14. Nat Genet 2003; 35: 258-63
107. Zamel N, McClean PA, Sandell PR, et al. Asthma on Tristan de Cunha: Looking for the genetic link. Am J Respir Crit Care Med 1996; 153: 1902-6
108. Slutsky AS, Zamel N. Genetics of asthma: the University of Toronto program. Am J Respir Crit Care Med 1997; 156 (4 Pt 2): S130-2
109. Templeton AR. The theory of speciation via the founder principle. Genetics 1980; 94: 1011-38
110. Laitinen T, Daly MJ, Rioux JD, et al. A susceptibility locus for asthma-related traits on chromosome 7 revealed by genome-wide scan in a founder population. Nat Genet 2001; 28: 87-91
111. Poon AH, Laprise C, Lemire M, et al. Association of vitamin D receptor genetic variants with susceptibility to asthma and atopy. Am J Respir Crit Care Med 2004; 170: 967-73
112. Slutsky AS, Zamel N. Genetics of asthma: University of Toronto. Clin Exp Allergy 1995; 25 (Suppl. 2): 33-4
113. Upton MN, McConnachie A, McSharry C, et al. Intergenerational 20 year trends in the prevalence of asthma and hay fever in adults: the Midspan family study surveys of parents and offspring. BMJ 2000; 321: 88-92
114. Thompson MD, Bowen RA, Wong BY, et al. Whole genome amplification of buccal cell DNA: genotyping concordance before and after multiple displacement amplification. Clin Chem Lab Med 2005; 43: 157-62
115. Maekawa A, Austen KF, Kanaoka Y. Targeted gene disruption reveals the role of cysteinyl leukotriene 1 receptor in the enhanced vascular permeability of mice undergoing acute inflammatory responses. J Biol Chem 2002; 277: 20820-4
116. Severien C, Artlich A, Jonas S, et al. Urinary excretion of leukotriene E-4 and eosinophil protein X in children with atopic asthma. Eur Respir J 2000; 16: 588-92
117. Takasaki J, Kamohara M, Matsumoto M, et al. The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor. Biochem Biophys Res Commun 2000; 274: 316-22
118. Figueroa DJ, Breyer RM, Defoe SK, et al. Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes. Am J Respir Crit Care Med 2001; 163: 226-33
119. Metters KM. Leukotriene receptors. J Lipid Mediat Cell Signal 1995; 12: 413-27
120. Mita H, Hasegawa M, Saito H, et al. Levels of cysteinyl leukotriene receptor mRNA in human peripheral leucocytes: significantly higher expression of cysteinyl leukotriene receptor 2 mRNA in eosinophils. Clin Exp Allergy 2001; 31: 1714-23
121. Kanaoka Y, Maekawa A, Penrose JF, et al. Attenuated zymosan-induced peritoneal vascular permeability and IgE dependent passive cutaneous anaphylaxis in mice lacking leukotriene C-4 synthase. J Biol Chem 2001; 276: 22608-13
122. Beller TC, Maekawa A, Friend DS, et al. Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary fibrosis in mice. J Biol Chem 2004; 279: 46129-34
123. Beller TC, Friend DS, Maekawa A, et al. Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis. Proc Natl Acad Sci U S A 2004; 101: 3047-52
124. Maekawa A, Kanaoka Y, Lam BK, et al. Identification in mice of two isoforms of the cysteinyl leukotriene 1 receptor that result from alternative splicing. Proc Natl Acad Sci U S A 2001; 98: 2256-61
125. Samuelsson B, Dahlen SE, Lindgren JA, et al. Leukotrienes and lipoxins; structures, biosynthesis, and biological effects. Science 1987; 237: 1171-6
126. Palmer LJ, Silverman ES, Weiss ST, et al. Pharmacogenetics of asthma. Am J Respir Crit Care Med 2002; 165: 861-6
127. Israel E. Genetics and the variability of treatment response in asthma. J Allergy Clin Immunol 2005; 115 (4 Suppl.): S532-8
128. Holgate ST, Bradding P, Sampson AP. Leukotriene antagonists and synthesis inhibitors: New directions in asthma therapy. J Allergy Clin Immunol 1996; 98: 1-13
129. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340: 197-206
130. Silverman ES, Du J, De Sanctis GT, et al. Egr-1 and Sp1 interact functionally with the 5-lipoxygenase promoter and its naturally occurring mutants. Am J Respir Cell Mol Biol 1998; 19: 316-23
131. Sayers I, Barton S, Rorke S, et al. Promoter polymorphism in the 5-lipoxygenase (ALOX5) and 5-lipoxygenase-activating protein (ALOX5AP) genes and asthma susceptibility in a Caucasian population. Clin Exp Allergy 2003; 33: 1103-10
132. Drazen JM, Yandava CN, Dube L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999; 22: 168-70
133. Sampson AP, Siddiqui S, Buchanan D, et al. Variant LTC4 synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000; 55 (Suppl. 2): S28-31
134. Reiss TF, Altman LC, Chervinsky P, et al. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LDT(4)) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996; 98: 528-34
135. Grossman J, Faiferman I, Dubb JW, et al. Results of the first US double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist. J Asthma 1997; 34: 321-8
136. Suissa S, Dennis R, Ernst P, et al. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126: 177-83
137. Jarvis B, Markham A. Montelukast: a review of its therapeutic potential in persistent asthma. Drugs 2000; 59: 891-928
138. Krawiec ME, Wenzel SE. Use of leukotriene antagonists in childhood asthma. Curr Opin Pediatr 1999 Dec;11(6):540-7. Review. Erratum in: Curr Opin Pediatr 2000 Feb; 12 (1): 96
139. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull 2000; 56: 1054-70
140. Yoshida S, Sakamoto H, Ishizaki Y, et al. Efficacy of leukotriene receptor antagonist in bronchial hyperresponsiveness and hypersensitivity to analgesic in aspirin-intolerant asthma. Clin Exp Allergy 2000; 30: 64-70
141. Obase Y, Shimoda T, Tomari S, et al. Effects of pranlukast on aspirin-induced bronchoconstriction: differences in chemical mediators between aspirin-intolerant and tolerant asthmatic patients. Ann Allergy Asthma Immunol 2001; 87: 74-9
142. Williams B, Noonan G, Reiss TF, et al. Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older. Clin Exp Allergy 2001; 31: 845-54
143. Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 2000; 105: 917-22
144. Noonan MJ, Chervinsky P, Brandon M, et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Eur Respir J 1998; 11: 1232-9
145. Woszczek G, Pawliczak R, Qi HY, et al. Functional characterization of human cysteinyl leukotriene 1 receptor gene structure. J Immunol 2005; 175: 5152-9
146. Kimura K, Noguchi E, Shibasaki M, et al. Linkage and association of atopic asthma to markers on chromosome 13 in the Japanese population. Hum Mol Genet 1999; 8: 1487-90
147. Rashid AJ, O'Dowd BF, George SR. Minireview: diversity and complexity of signaling through peptidergic G protein-coupled receptors. Endocrinology 2004; 145: 2645-52
148. Tudhope SR, Cuthbert NJ, Abram TS, et al. Bay-U9773: a novel antagonist of cysteinyl-leukotrienes with activity against 2 receptor subtypes. Eur J Pharmacol 1994; 264: 317-23
149. Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000; 289: 739-45
150. Pillai SG, Cousens DJ, Barnes AA, et al. A coding polymorphism in the CYSLT2 receptor with reduced affinity to LTD4 is associated with asthma. Pharmacogenetics 2004; 14: 627-33
151. Cookson WOCM, Faux JA, Sharp PA, et al. Linkage between immunoglobulin E responses underlying asthma and rhinitis and chromosome-11Q. Lancet 1989; I: 1292-5
152. Ono SJ. Molecular genetics of allergic diseases. Annu Rev Immunol 2000; 18: 347-66
153. Fukai H, Ogasawara Y, Migita O, et al. Association between a polymorphism in cysteinyl leukotriene receptor 2 on chromosome 13q14 and atopic asthma. Pharmacogenetics 2004; 14: 683-90
154. Carlson CS, Eberle MA, Rieder MJ, et al. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004; 74: 106-20
155. FBAT program [online]. Available from URL: http://biostat.harvard.edu/ ∼fbat/fbat.htm [Accessed 2006 Dec 1]
156. Spiegel AM. Defects in G protein-coupled signal transduction in human disease. Annu Rev Physiol 1996; 58: 143-70
157. Milligan G. Strategies to identify ligands for orphan G-protein-coupled receptors. Biochem Soc Trans 2002; 30: 789-93
158. Spiegel AM, Weinstein LS. Inherited diseases involving G proteins and G protein-coupled receptors. Annu Rev Med 2004; 55: 27-39
159. Bautz F, Denzlinger C, Kanz L, et al. Chemotaxis and transendothelial migration of CD34(+) hematopoietic progenitor cells induced by the inflammatory mediator leukotriene D4 are mediated by the 7-transmembrane receptor CysLT1. Blood 2001; 97: 3433-40
160. Horn F, Bywater R, Krause G, et al. The interaction of class B G protein-coupled receptors with their hormones. Receptors Channels 1998; 5: 305-14
161. Horn F, Vriend G. G protein-coupled receptors in silico. J Mol Med 1998; 76: 464-8
162. Renzi PM. Antileukotriene agents in asthma: the dart that kills the elephant? CMAJ 1999; 160: 217-23
163. Capra V, Thompson MD, Cole DEC, et al. Cysteinyl-leukotrienes and their receptors in health and disease. Med Res Rev. Epub 2006 Aug 7